| This week's sponsor is Precision Oncology. | |  | Optimize registration success: what you need to know.
Novel drug applications with biomarkers achieve 25.9% greater probability of approval than applications without. Learn the biomarker difference and 5 other key strategies.
Get the free Oncology Brief |
Top Stories Thursday, November 10, 2016 Alongside its Q3 results today AstraZeneca announced that it was dropping plans to gain an early regulatory review for its checkpoint inhibitor durvalumab in head and neck cancers. Thursday, November 10, 2016 The FDA has removed the partial clinical hold it placed on an Adaptimmune trial in August. The move clears Adaptimmune to start enrolling patients with myxoid round cell liposarcoma in a trial of its GlaxoSmithKline-partnered NY‑ESO T-cell therapy. Thursday, November 10, 2016 Two months ago Novavax announced that its Phase III RSV F vaccine flopped fantastically, and now, with a sense of inevitability, it has announced a “corporate restructure.” Wednesday, November 9, 2016 Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry. The initiative will offer funding and access to Evotec’s drug discovery platform to projects that are an experiment or two away from being ready to be spun out into biotech startups or outlicensed. Wednesday, November 9, 2016 IBM Watson is kicking off another oncology partnership, this time with the Broad Institute of MIT and Harvard University. The $50 million tie-up will have the pair examining genome data from 10,000 drug-resistant tumors and cell line studies, with the goal of understanding the drivers behind cancer drug resistance and developing new treatments. Tuesday, November 8, 2016 Induced pluripotent stem cell specialist Axiogenesis AG has partnered with ion channel CRO Metrion Biosciences to develop human iPSC-derived cardiomyocytes and neurons for drug discovery applications. Thursday, November 10, 2016 AstraZeneca’s top line got hit hard in Q3, and much of the pain came from plummeting Crestor sales. But the British drugmaker had underperformance in a couple key therapy areas to blame, too. | This week's sponsor is Catalent. | |  | eBook | Healthy Aging: Improved Dose Forms for Aging Population
As healthy aging becomes a bigger concern in the U.S., manufacturing companies are finding a new opportunities to serve this audience as they turn increasingly to OTC treatments. Download this eBook to learn how a successful partnership between OTC brands and manufacturing companies can improve health outcomes for the growing population of empowered seniors. |
| | | Merrimack is, according to sources speaking to Reuters, on the brink of selling off some of its assets, or signing a licensing deal. Story Micro cap Anthera has seen its experimental lupus med blisibimod narrowly fail a late-stage study after not hitting its primary endpoint, prompting its shares to fall 20% premarket. Release Amgen has signed a collab deal with Janssen that will see the pair co-fund tests using Kyprolis and Darzalex in patients with multiple myeloma. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
